Connie Shi is a Dermatology physician affiliated with Brigham and Women's Hospital. OpenAlex indexes 73 publications with 279 citations (h-index 10).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
75 Francis St
Boston, MA 02115
Telephone
617-732-5500Provider last certified this registry record 8 Mar 2023.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year20251 payment
- BeOne Medicines USA, Inc.Program year20252 payments
- Incyte CorporationProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
30.6%Corticosteroid30.6%Betamethasone Diprop Augmented32%Betamethasone Dipropionate25%Hydrocortisone22%Clobetasol Propionate21%Part D≥43 patientsDermatology
27.8%Corticosteroid14%Triamcinolone Acetonide100%Part D≥55 patientsInterleukin-4 Receptor alpha Antagonist8.4%Dupixent Pen56%Dupixent Syringe44%Part D<11 patients+ 2 more classes in this area
Anti-infectives
23%Azole Antifungal15.5%Ketoconazole100%Part D≥51 patientsNitroimidazole Antimicrobial2.8%Metronidazole100%Part D≥11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Interstitial granulomatous drug reaction associated with tyrosine kinase inhibitor dasatinib
Leukemia & lymphoma/Leukemia and lymphoma
2026 - Isotretinoin and acitretin for EGFR-, MEK-, and BRAF-inhibitor-associated acneiform eruptions: A 10-year multicenter retrospective analysis
Journal of the American Academy of Dermatology
2026 - Cutaneous toxicities associated with epidermal growth factor receptor and mesenchymal epithelial transition factor dual blockade via bispecific antibody amivantamab
Journal of the American Academy of Dermatology
2025 - Severity and progression of dermatologic adverse events associated with tebentafusp: A retrospective multicenter cohort study
Journal of the American Academy of Dermatology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Paul Ridker, MD
Brigham and Women's Hospital
Scott Solomon, MD
Brigham and Women's Hospital
Dennis Selkoe, MD
Brigham and Women's Hospital
Marc Pfeffer, MD
Brigham and Women's Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”